Abstract
Individuals with mild cognitive impairment (MCI) are at increased risk for Dementia of Alzheimers type (DAT), vascular dementia (VaD), Lewy Body (LBD) and Fronto-temporal dementias (FTD). Risk factors and conversion rates of MCI to dementia have not been thoroughly investigated in developing countries. Chinese and English versions of Mini-Mental State Examination were administered serially among well-matched subjects from two clinics located in Xian, China and Houston, USA. Subtle cognitive impairments were weighed according to MCI criteria as defined previously. Subjects with MCI were followed for an additional 3 years after their identification. Diagnoses of VaD and DAT were made according to established criteria. During screening period, 73 American and 65 Chinese individuals were identified with MCI. After 3 years of MCI follow-up, of the 73 American MCI subjects, 35 (47.9%) developed DAT and 15 (20.5%) developed VaD. Of the 65 Chinese MCI subjects, 12 (18.5%) developed DAT and 19 (29.2%) developed VaD. According to Kaplan-Meier analysis, Chinese MCI subjects, despite their lower educational level, are 1.7 times less likely to progress to DAT and 2.3 times more likely to progress to VaD than American subjects within 3 years of MCI being identified (p < 0.01). Data suggest that progression rates of MCI vary considerably among subjects from two countries. American MCI subjects are more prone to DAT, while Chinese subjects are more prone to VaD. Differences in genetic factors, cultures, educational levels, and preventive treatments of vascular risk factors are proposed as responsible for this uneven geographic distribution for different types of dementia.
Keywords: Aging, Alzheimer Disease (DAT), Cross-Cultural Comparison, Vascular Dementia (VAD), Mild Cognitive Impairment (MCI), Psychometrics
Current Alzheimer Research
Title: Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Volume: 1 Issue: 1
Author(s): Gelin Xu, John Stirling Meyer, Yuangui Huang, Guanghui Chen, Munir Chowdhury and Minh Quach
Affiliation:
Keywords: Aging, Alzheimer Disease (DAT), Cross-Cultural Comparison, Vascular Dementia (VAD), Mild Cognitive Impairment (MCI), Psychometrics
Abstract: Individuals with mild cognitive impairment (MCI) are at increased risk for Dementia of Alzheimers type (DAT), vascular dementia (VaD), Lewy Body (LBD) and Fronto-temporal dementias (FTD). Risk factors and conversion rates of MCI to dementia have not been thoroughly investigated in developing countries. Chinese and English versions of Mini-Mental State Examination were administered serially among well-matched subjects from two clinics located in Xian, China and Houston, USA. Subtle cognitive impairments were weighed according to MCI criteria as defined previously. Subjects with MCI were followed for an additional 3 years after their identification. Diagnoses of VaD and DAT were made according to established criteria. During screening period, 73 American and 65 Chinese individuals were identified with MCI. After 3 years of MCI follow-up, of the 73 American MCI subjects, 35 (47.9%) developed DAT and 15 (20.5%) developed VaD. Of the 65 Chinese MCI subjects, 12 (18.5%) developed DAT and 19 (29.2%) developed VaD. According to Kaplan-Meier analysis, Chinese MCI subjects, despite their lower educational level, are 1.7 times less likely to progress to DAT and 2.3 times more likely to progress to VaD than American subjects within 3 years of MCI being identified (p < 0.01). Data suggest that progression rates of MCI vary considerably among subjects from two countries. American MCI subjects are more prone to DAT, while Chinese subjects are more prone to VaD. Differences in genetic factors, cultures, educational levels, and preventive treatments of vascular risk factors are proposed as responsible for this uneven geographic distribution for different types of dementia.
Export Options
About this article
Cite this article as:
Xu Gelin, Meyer Stirling John, Huang Yuangui, Chen Guanghui, Chowdhury Munir and Quach Minh, Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA, Current Alzheimer Research 2004; 1 (1) . https://dx.doi.org/10.2174/1567205043480564
| DOI https://dx.doi.org/10.2174/1567205043480564 |
Print ISSN 1567-2050 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Blood Tests: Advancements and the Future of Point-of-Care
The recent FDA approval of lecanemab (Leqembi), the first treatment for Alzheimer’s disease targeting early stages and mild cognitive impairment, has brought renewed hope for the therapeutic future of this devastating condition. While the exact causes and mechanisms of Alzheimer’s disease remain obscure, there is an urgent consensus on the ...read more
Atypical Alzheimer’s disease: towards inclusion into disease-modifying clinical trials
Patients with non-amnestic atypical variants of Alzheimer’s disease show considerable heterogeneity in clinical characteristics, including visual, language and behavioral impairments, and often have a young age onset. Current clinical trials for anti-amyloid therapies do not sufficiently account for this heterogeneity, and it is unclear whether current treatments tested in amnestic ...read more
Drug Discovery and Possible Therapeutic Developments in Neurological Disorders Alzheimer’s Disease and Tauopathy
A critical appraisal Alzheimer's disease (AD) is a devastating mental illness in society and the etiology and pathogenesis of AD are still poorly understood. One of the key hallmark pathological proteins of AD is tau, where the pathophysiology and the functional relationships between hyperphosphorylation of tau and synaptic damage in ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spatial Correlations between the Vacuolation, Prion Protein (PrPsc) Deposits and the Cerebral Blood Vessels in Sporadic Creutzfeldt-Jakob Disease
Current Neurovascular Research Prevalence of Sinusitis Detected by Magnetic Resonance Imaging in Subjects with Dementia or Alzheimer’s Disease
Current Alzheimer Research Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders
Current Drug Metabolism The HIV Pandemic: A Forgotten Crisis?
Current Drug Targets - Infectious Disorders Oral Supplements of <i>Ginkgo biloba</i> Extract Alleviate Neuroinflammation, Oxidative Impairments and Neurotoxicity in Rotenone-Induced Parkinsonian Rats
Current Pharmaceutical Biotechnology Non-Amyloid PET Imaging Biomarkers for Neurodegeneration: Focus on Tau, Alpha-Synuclein and Neuroinflammation
Current Alzheimer Research Insulin Resistance in Brain and Possible Therapeutic Approaches
Current Vascular Pharmacology Editorial (Hot Topic: Therapeutic Targets in Neurodegenerative Diseases)
Current Enzyme Inhibition Hybrid Molecules Incorporating Natural Products: Applications in Cancer Therapy, Neurodegenerative Disorders and Beyond
Current Medicinal Chemistry Pharmacologic Treatment for Prehypertension: To Treat or Not to Treat?
Recent Patents on Cardiovascular Drug Discovery An Apple Plus a Brazil Nut a Day Keeps the Doctors Away: Antioxidant Capacity of Foods and their Health Benefits
Current Pharmaceutical Design The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Current Pharmaceutical Design Antioxidants as a Potential Therapy Against Age-Related Neurodegenerative Diseases: Amyloid Beta Toxicity and Alzheimers Disease
Current Pharmaceutical Design Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Conditional Tat Protein Brain Expression in the GT-tg Bigenic Mouse Induces Cerebral Fractional Anisotropy Abnormalities
Current HIV Research Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Cell Clocks and Neuronal Networks: Neuron Ticking and Synchronization in Aging and Aging-Related Neurodegenerative Disease
Current Alzheimer Research New Agents Promote Neuroprotection in Parkinson’s Disease Models
CNS & Neurological Disorders - Drug Targets Modeling Parkinson’s Disease in Zebrafish
CNS & Neurological Disorders - Drug Targets Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry





